Please login to the form below

Not currently logged in

UK launch for gastrointestinal pharma firm

Belgian gastrointestinal pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate

Belgian gastrointestinal (GI) pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate.

Movetis (UK) will focus on the production of novel drugs to be used in the treatment of GI-related diseases where current options are limited.

The UK team includes eight representatives experienced in GI disorders. They will work with a range of products including Resolor (prucalopride), a treatment for chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor was launched in the UK in March, 2010.

The company has said it plans further research involving prucalopride beyond its current indication.

Two products are currently in phase II development for Movetis, with a further two prioritised compounds in preclinical development. All products are aimed at addressing unmet needs in GI treatment.

David Trevor, general manager of Movetis (UK) said "The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease."

28th July 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....